腺样囊性乳腺癌的治疗模式和临床结局：单中心经验。
Treatment Patterns and Clinical Outcomes of Adenoid Cystic Breast Carcinoma: A Single-Institution Experience.
机构信息
14640 Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
出版信息
Am Surg. 2020 Dec;86(12):1684-1690. doi: 10.1177/0003134820942287. Epub 2020 Aug 26.
BACKGROUND
Adenoid cystic breast carcinoma (ACC) is a rare subtype of triple-negative breast cancer. We aim to characterize the treatment patterns and clinical outcomes of women diagnosed with ACC at a large medical center.
METHODS
Female patients diagnosed with ACC at our institution between 2009 and 2019 were retrospectively identified. Patients with limited clinicopathologic data were excluded.
RESULTS
In our final study cohort (n = 9), the majority of ACCs (6/9, 66.7%) were hormone receptor (-) (HR-) and HER-2/neu (-) (HER2-), while 3 ACCs were HR+ HER2-. Two patients received adjuvant chemotherapy, and 4 patients received adjuvant radiotherapy. The crude local and distant recurrence rate of our cohort was 22.2% and 11.1% (median follow-up of 36 months).
CONCLUSIONS
The majority of ACCs were triple negative but some ACCs were HR+. The unadjusted local and distant recurrence rates were not negligible, suggesting that adjuvant chemotherapy and radiotherapy may be warranted in select cases.
背景
腺样囊性乳腺癌（ACC）是三阴性乳腺癌的一种罕见亚型。我们旨在描述在一家大型医疗中心诊断为 ACC 的女性的治疗模式和临床结局。
方法
我们回顾性地确定了我院 2009 年至 2019 年间诊断为 ACC 的女性患者。排除了临床病理数据有限的患者。
结果
在我们的最终研究队列中（n = 9），大多数 ACC（6/9，66.7%）为激素受体（-）（HR-）和 HER-2/neu（-）（HER2-），而 3 例 ACC 为 HR+HER2-。2 例患者接受了辅助化疗，4 例患者接受了辅助放疗。本队列的粗局部和远处复发率分别为 22.2%和 11.1%（中位随访 36 个月）。
结论
大多数 ACC 为三阴性，但有些 ACC 为 HR+。未经调整的局部和远处复发率不容忽视，这表明在某些情况下可能需要辅助化疗和放疗。
Zotero 插件